Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research
- PMID: 22125594
- PMCID: PMC3219640
- DOI: 10.1371/journal.pone.0026100
Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research
Abstract
Cancer therapy selects for cancer cells resistant to treatment, a process that is fundamentally evolutionary. To what extent, however, is the evolutionary perspective employed in research on therapeutic resistance and relapse? We analyzed 6,228 papers on therapeutic resistance and/or relapse in cancers and found that the use of evolution terms in abstracts has remained at about 1% since the 1980s. However, detailed coding of 22 recent papers revealed a higher proportion of papers using evolutionary methods or evolutionary theory, although this number is still less than 10%. Despite the fact that relapse and therapeutic resistance is essentially an evolutionary process, it appears that this framework has not permeated research. This represents an unrealized opportunity for advances in research on therapeutic resistance.
Conflict of interest statement
Figures





References
-
- Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, et al. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol. 2006;208:461–472. - PubMed
-
- Murphy DS, Hoare SF, Going JJ, Mallon EE, George WD, et al. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst. 1995;87:1694–1704. - PubMed
-
- Harada T, Okita K, Shiraishi K, Kusano N, Kondoh S, et al. Interglandular cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer. Cancer Res. 2002;62:835–839. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources